Keros Therapeutics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-22. Between them they name 3 people, with 2 appointments and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: Keith Regnante, Chief Financial Officer, effective 2026-08-03
Executive Transition On July 17, 2026, Keith Regnante resigned from his role as Chief Financial Officer of Keros Therapeutics, Inc. (the "Company"), effective August 3, 2026 (the "Separation Date"), to pursue other opportunities.
Appointed: Annita Tanini, Controller, effective 2026-08-04
In connection with Mr. Regnante's departure, the Company's Board of Directors (the "Board") appointed Annita Tanini, the Company's Corporate Controller and Vice President, Finance, as the Company's interim principal financial officer and principal accounting officer, effective as of August 4, 2026.
Appointed: Anne Prener, Director
Dr. Prener was appointed as a Class III director with a term expiring at the Company's 2029 annual meeting of stockholders.
Find people with the same kind of experience as the Chief Financial Officer at Keros Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Keros Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Keros Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Keros Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Keros Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.